Ponce Therapeutics – Ponce Therapeutics

Dan Tetzl In K2 BioLabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

Ponce Therapeutic's ("Ponce") lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting senescent keratinocytes and fibroblasts in the skin Speratum Biopharma ("Speratum")...

Dan Tetzl In K2 BioLabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

New Biotechnology Research Accelerator Launches in Houston

K2-BioLabs offers “big company” resources that accommodate “small company” budgets Rapha Portfolio Company PONCE Therapeutics, Inc. is an investor and the first tenant of K2 Bio Houston, TX, June 14,...

Kevin Slawin In Ponce Therapeutics, Portfolio, Rapha Capital Management

Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin

Rapha Capital Management Leads Convertible Note Financing Miami, FL – February 8, 2021 – Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to…